Roche (RHHBY) News Today → Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad) Free RHHBY Stock Alerts $32.01 +0.44 (+1.39%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartDividendHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartDividendHeadlinesInsider TradesOwnershipShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 6:44 AM | americanbankingnews.comRoche (OTCMKTS:RHHBY) Coverage Initiated by Analysts at The Goldman Sachs GroupMay 29, 2024 | markets.businessinsider.comFDA Grants Priority Review To Genentech's Inavolisib For Advanced HR+, HER2- Breast Cancer MutationMay 29, 2024 | finance.yahoo.comFDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA MutationMay 29, 2024 | finance.yahoo.comFDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutationMay 29, 2024 | businesswire.comFDA Grants Priority Review to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA MutationMay 29, 2024 | globenewswire.comFDA grants Priority Review to Roche's inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutationMay 27, 2024 | globenewswire.comChanges to the Roche Enlarged Corporate Executive CommitteeMay 27, 2024 | prnewswire.comRoche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testingMay 24, 2024 | msn.comPharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & MoreMay 22, 2024 | markets.businessinsider.comRoche Cancer Drug Gets Breakthrough Therapy DesignationMay 22, 2024 | markets.businessinsider.comRoche: FDA Grants Breakthrough Device Designation For Bood Test Measuring Lp(a)May 22, 2024 | globenewswire.comRoche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular riskMay 21, 2024 | nasdaq.comRoche, Genentech: Inavolisib Gets FDA Breakthrough Status To Treat Breast Cancer With MutationMay 21, 2024 | finance.yahoo.comFDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA MutationMay 21, 2024 | businesswire.comFDA Grants Breakthrough Therapy Designation to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA MutationMay 21, 2024 | globenewswire.comFDA grants Breakthrough Therapy Designation to Roche's inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutationMay 16, 2024 | finance.yahoo.comRoche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug CandidateMay 16, 2024 | msn.comRoche ramps up obesity-drug competition with early-stage trial resultsMay 16, 2024 | msn.comRoche obesity therapy leads to ~19% weight loss in Phase 1 trialMay 16, 2024 | cnbc.comRoche says weight loss drug shows promising results in early trialMay 16, 2024 | wsj.comRoche Climbs After Weight-Loss Drug Shows EfficacyMay 16, 2024 | reuters.comRoche shares gain on obesity drug results from early-stage trialMay 16, 2024 | businesswire.comGenentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With ObesityMay 16, 2024 | globenewswire.com[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesityMay 15, 2024 | markets.businessinsider.comFDA Approves Roche's HPV Self-Collection Solution In Cervical CancerMay 15, 2024 | reuters.comRoche says FDA approves HPV self-test in USMay 15, 2024 | globenewswire.comRoche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancerMay 6, 2024 | marketbeat.comWhy Invest in Biotech Stocks (RHHBY)One fascinating sector to invest in is the biotech sector which includes companies involved in the research and development of therapeutics and vaccinesApril 26, 2024 | finance.yahoo.comUS FDA says about 1 in 5 commercial milk samples tested positive for bird flu tracesApril 25, 2024 | marketbeat.comRoche (OTCMKTS:RHHBY) Sets New 12-Month Low at $29.80Roche (OTCMKTS:RHHBY) Hits New 52-Week Low at $29.80April 25, 2024 | marketbeat.comRoche Holding AG (OTCMKTS:RHHBY) Shares Sold by Meritage Portfolio ManagementMeritage Portfolio Management trimmed its position in Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 58.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 60,891 shares of the company's stock after selling 86,662 shApril 25, 2024 | businesswire.comVividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN)April 24, 2024 | ft.comRoche cuts drug pipeline in effort to revitalise businessApril 24, 2024 | markets.businessinsider.comHookipa Received FDA Clearance For HB-700 For Treatment Of KRAS-Mutated CancersApril 24, 2024 | benzinga.comWhy Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?April 24, 2024 | markets.businessinsider.comRoche Q1 Group Sales Down 6%; Confirms 2024 Outlook - Quick FactsApril 24, 2024 | cnbc.comSwiss pharma giant Roche's first-quarter sales edge higher as its emerges from post-Covid-19 slumpApril 24, 2024 | reuters.comRoche Q1 sales down 6% on forex effect, loss of COVID revenueApril 24, 2024 | globenewswire.com[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19April 19, 2024 | msn.comPharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study DataApril 19, 2024 | finanznachrichten.deF. Hoffmann-La Roche Ltd: FDA approves Roche's Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancerApril 19, 2024 | finance.yahoo.comFDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancerApril 19, 2024 | markets.businessinsider.comRoche Announces FDA Approval For AlecensaApril 19, 2024 | globenewswire.comFDA approves Roche's Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancerApril 18, 2024 | markets.businessinsider.comFDA Approves Genentech's Alecensa For ALK-positive Early-Stage Lung CancerApril 18, 2024 | businesswire.comFDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung CancerApril 17, 2024 | finance.yahoo.comGenentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MSApril 16, 2024 | finance.yahoo.comCelebration Obstetrics & Gynecology Now Accepting Partner's Direct Health InsuranceApril 15, 2024 | msn.comRoche's Lymphoma Drug With Chemo Extends Survival In Pretreated PatientsApril 15, 2024 | businesswire.comGenentech's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study Get Roche News Delivered to You Automatically Sign up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter. Email Address The Only Energy Play You Should Be Looking At (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy. Click here to get all the information about it. RHHBY Media Mentions By Week RHHBY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RHHBY News Sentiment▼0.220.76▲Average Medical News Sentiment RHHBY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RHHBY Articles This Week▼104▲RHHBY Articles Average Week Get Roche News Delivered to You Automatically Sign up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Capstone News EOM Pharmaceuticals News Genmab A/S News Hypera News IMV News International Stem Cell News LAVA Therapeutics News Mainz Biomed News NLS Pharmaceutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:RHHBY) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBiden replacement revealed?Paradigm PressThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roche Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
